MX2015007893A - Uso de factor antisecretorio (fa) en el tratamiento de un glioblastoma. - Google Patents
Uso de factor antisecretorio (fa) en el tratamiento de un glioblastoma.Info
- Publication number
- MX2015007893A MX2015007893A MX2015007893A MX2015007893A MX2015007893A MX 2015007893 A MX2015007893 A MX 2015007893A MX 2015007893 A MX2015007893 A MX 2015007893A MX 2015007893 A MX2015007893 A MX 2015007893A MX 2015007893 A MX2015007893 A MX 2015007893A
- Authority
- MX
- Mexico
- Prior art keywords
- antisecretory factor
- pharmaceutical substance
- substance
- formulation
- glioblastoma treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Reproductive Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Gynecology & Obstetrics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Physiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención está relacionada con el uso de un factor antisecretorio (FA) en forma de proteína, péptido, derivado, homólogo, y/o un fragmento de uno de ellos, que posee una actividad funcional equivalente, y/o una sal de uno de ellos farmacológicamente activa, para tratar un glioblastoma. En una realización, las proteínas FA son utilizadas para optimizar el reparto y la captación celular de una sustancia y/o formulación farmacológica, o el reparto de un gen. Típicamente, dicha sustancia y/o formulación farmacológica comprende una medicación anticancerígena, terapia por radiación, una sustancia antibiótica, un compuesto immunoactivo o una medicación indicada para heridas postraumáticas, neurodegeneración, o una condición inflamatoria.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1251473 | 2012-12-20 | ||
| PCT/EP2013/077747 WO2014096384A1 (en) | 2012-12-20 | 2013-12-20 | Use of antisecretory factor (af) in glioblastoma treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015007893A true MX2015007893A (es) | 2016-03-04 |
| MX360658B MX360658B (es) | 2018-11-12 |
Family
ID=49958419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015007893A MX360658B (es) | 2012-12-20 | 2013-12-20 | Uso de factor antisecretorio (fa) en el tratamiento de un glioblastoma. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20190192622A1 (es) |
| EP (1) | EP2934564B1 (es) |
| JP (1) | JP6204490B2 (es) |
| KR (1) | KR101838788B1 (es) |
| CN (1) | CN105025916B (es) |
| AU (1) | AU2013366509B2 (es) |
| CA (2) | CA3036216A1 (es) |
| DK (1) | DK2934564T3 (es) |
| ES (1) | ES2680551T3 (es) |
| IL (1) | IL239298B (es) |
| MX (1) | MX360658B (es) |
| NZ (1) | NZ708860A (es) |
| PL (1) | PL2934564T3 (es) |
| WO (1) | WO2014096384A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2992057C (en) | 2015-07-10 | 2021-07-20 | Lantmannen As-Faktor Ab | Process for producing egg yolk with high content of af-16 |
| AU2017299131B2 (en) * | 2016-07-18 | 2020-05-21 | Lantmännen As-Faktor Ab | Antisecretory Factor 17 |
| CA3103164A1 (en) | 2018-06-28 | 2020-01-02 | Lantmannen Medical Ab | Antisecretory factor for use in treatment and/or prevention of acute respiratory failure |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE513496C2 (sv) * | 1998-12-17 | 2000-09-18 | Rural Patent Svenska Ab | NASP-berikad äggula samt dess användning |
| GB0322645D0 (en) * | 2003-09-26 | 2003-10-29 | Melacure Therapeutics Ab | Use of antisecretory factor peptides |
| US20060257317A1 (en) * | 2005-05-04 | 2006-11-16 | Duke University | Combination therapy in the treatment of cancer |
| CA2650344C (en) * | 2006-04-27 | 2017-10-31 | Lantmannen As-Faktor Ab | Use of antisecretory protein to treat intraocular hypertension |
| WO2010093324A1 (en) * | 2009-02-11 | 2010-08-19 | Lantmännen As-Faktor Ab | Use of antisecretory factors (af) for optimizing cellular uptake |
| US8946226B2 (en) * | 2008-07-29 | 2015-02-03 | Nerviano Medical Sciences S.R.L. | Use of CDK inhibitor for the treatment of glioma |
| CA2819240C (en) * | 2010-12-02 | 2021-06-15 | Ecosynthetix Ltd. | Aptamer bioconjugate drug delivery device |
-
2013
- 2013-12-20 AU AU2013366509A patent/AU2013366509B2/en active Active
- 2013-12-20 DK DK13821470.5T patent/DK2934564T3/en active
- 2013-12-20 JP JP2015548644A patent/JP6204490B2/ja active Active
- 2013-12-20 CN CN201380070283.0A patent/CN105025916B/zh active Active
- 2013-12-20 CA CA3036216A patent/CA3036216A1/en not_active Abandoned
- 2013-12-20 KR KR1020157017910A patent/KR101838788B1/ko active IP Right Grant
- 2013-12-20 ES ES13821470.5T patent/ES2680551T3/es active Active
- 2013-12-20 MX MX2015007893A patent/MX360658B/es active IP Right Grant
- 2013-12-20 PL PL13821470T patent/PL2934564T3/pl unknown
- 2013-12-20 NZ NZ708860A patent/NZ708860A/en not_active IP Right Cessation
- 2013-12-20 US US14/652,868 patent/US20190192622A1/en not_active Abandoned
- 2013-12-20 EP EP13821470.5A patent/EP2934564B1/en active Active
- 2013-12-20 CA CA2894948A patent/CA2894948C/en active Active
- 2013-12-20 WO PCT/EP2013/077747 patent/WO2014096384A1/en active Application Filing
-
2015
- 2015-06-09 IL IL239298A patent/IL239298B/en active IP Right Grant
-
2021
- 2021-12-28 US US17/563,532 patent/US20220118047A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL239298A0 (en) | 2015-07-30 |
| CA3036216A1 (en) | 2014-06-26 |
| MX360658B (es) | 2018-11-12 |
| CA2894948A1 (en) | 2014-06-26 |
| IL239298B (en) | 2019-12-31 |
| DK2934564T3 (en) | 2018-08-06 |
| ES2680551T3 (es) | 2018-09-10 |
| NZ708860A (en) | 2016-09-30 |
| PL2934564T3 (pl) | 2018-09-28 |
| KR20150096687A (ko) | 2015-08-25 |
| EP2934564A1 (en) | 2015-10-28 |
| CN105025916A (zh) | 2015-11-04 |
| JP6204490B2 (ja) | 2017-09-27 |
| CN105025916B (zh) | 2020-03-10 |
| KR101838788B1 (ko) | 2018-03-14 |
| WO2014096384A1 (en) | 2014-06-26 |
| AU2013366509A1 (en) | 2015-07-02 |
| CA2894948C (en) | 2022-07-19 |
| US20220118047A1 (en) | 2022-04-21 |
| EP2934564B1 (en) | 2018-05-23 |
| US20190192622A1 (en) | 2019-06-27 |
| JP2016505588A (ja) | 2016-02-25 |
| AU2013366509B2 (en) | 2016-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121373T1 (el) | Μεθοδος και φαρμακοτεχνικη μορφη για εισπνοη | |
| WO2014062697A3 (en) | Drug delivery conjugates containing unnatural amino acids and methods for using | |
| BR112016000561B8 (pt) | Compostos terapeuticamente ativos, uso dos mesmos, composição farmacêutica e uso da mesma | |
| WO2017044894A3 (en) | Cartilage-homing peptides | |
| MX2015005798A (es) | Terapia de combinacion. | |
| NZ701573A (en) | Carriers for improved drug delivery | |
| EA201491299A1 (ru) | Карбаматные соединения, их получение и применение | |
| MX2016008362A (es) | Combinaciones farmaceuticas. | |
| BR112017005736A2 (pt) | macrociclos peptidomiméticos e formulações dos mesmos | |
| MY166014A (en) | Combination therapy methods for treating proliferative diseases | |
| EA201290712A1 (ru) | Альфа-излучающие комплексы | |
| WO2016210376A3 (en) | Therapeutic peptides and methods of use thereof | |
| EA201501054A1 (ru) | Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы | |
| PH12014502366A1 (en) | Injectable formulation | |
| EA200802350A2 (ru) | Система доставки лекарств | |
| NZ704285A (en) | Protozoan variant-specific surface proteins (vsp) as carriers for oral drug delivery | |
| HK1232242A1 (zh) | 用於癌症靶向治療的包含基於重組血紅蛋白蛋白質或亞基的治療劑的藥物組合物 | |
| MX339243B (es) | Derivados fusionados sustituidos de imidazol, composiciones farmaceuticas y metodos de uso de los mismos. | |
| NZ708860A (en) | Use of antisecretory factor (af) in glioblastoma treatment | |
| EA201491352A1 (ru) | Способ лечения рака груди | |
| AU2012280776B2 (en) | Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases | |
| EP4001404A4 (en) | VIRUS AND TUMOR THERAPY FOR TARGETED KILLING OF TUMOR CELLS | |
| EA201590847A1 (ru) | Новые ингибиторы rock | |
| UA115250C2 (uk) | Фармацевтичні комбінації | |
| MX2011012659A (es) | Terapia con vacunas para neovascularizacion coroidea. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |